メタボリックシンドロームの効果的管理に対する障壁

Abstract

In This Issue...

Decision Resources, Inc., forecasts that the market for metabolic syndrome therapies will increase from $9.7 billion in 2003 to $12.8 billion in 2013. This market has enormous untapped potential, especially in Europe, but several major barriers (e.g., a lack of consensus on the definition of the disease, underdiagnosis, poor management, difficulties in the licensing of new therapies, reimbursement restrictions) have constrained growth. In this report, we consider the problems resulting from the lack of a consensus definition of metabolic syndrome. We then examine how limited knowledge and inadequate screening have contributed to underdiagnosis of the disease. We review therapeutic options and assess the reimbursement environment for metabolic syndrome therapeutics. Further, we analyze the challenges that face drugs in development for this disorder and the consequences of a renewed debate over the validity of metabolic syndrome as a distinct disease. We conclude with an assessment of the outlook and implications for the pharmaceutical industry.

Table of Contents

Overview

Lack of Consensus on Disease Definition

Underdiagnosis

Therapeutic Options

Reimbursement Environment

Drugs in Development

Validity of Metabolic Syndrome As a Distinct Disease

Outlook and Implications for the Pharmaceutical Industry